SCHEMBL213884

SCHEMBL213884

Cc1ccc(Br)cc1-n1cnc(C(N)=O)c1C(=O)Nc1nc(C)c(C)[nH]1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.33
SORT1 Q99523 1/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
GABRG2 P18507 4/20 0.31
GABRB3 P28472 4/20 0.31
GABRA5 P31644 4/20 0.31
GABRA1 P14867 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRA6 Q16445 1/20 0.31
SIK1 P57059 1/20 0.31
SIK2 Q9H0K1 1/20 0.31
SIK3 Q9Y2K2 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213991 0.85 GABRG2 (0.31) HCAR1SORT1GABRG2GABRB3GABRA5
SCHEMBL213893 0.84 MAPT (0.35) HCAR1MAPTGABRG2GABRB3GABRA5
SCHEMBL215845 0.84 IRAK4 (0.39) RAB9AKDM4ELMNAMAPTL3MBTL1
SCHEMBL215374 0.84 ABL1 (0.37) HCAR1RAB9AKDM4ELMNAMAPT
SCHEMBL214926 0.83 RAB9A (0.37) HCAR1RAB9AKDM4ELMNAMAPT
SCHEMBL214517 0.83 RAB9A (0.37) RAB9AKDM4ELMNAMAPTMEN1
SCHEMBL214609 0.82 MAOB (0.46) RAB9AKDM4ELMNAMAPTMEN1
SCHEMBL213975 0.81 KMT2A (0.42) RAB9AKDM4ELMNAMAPTL3MBTL1
SCHEMBL215824 0.81 RAB9A (0.41) RAB9AKDM4ELMNAMAPTMEN1
SCHEMBL215407 0.80 MTOR (0.38) HCAR1SORT1RAB9AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 HCAR1 4180/4885SORT1 3250/4885RAB9A 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.